etidronate has been researched along with Basilar Impression in 2 studies
Etidronic Acid: A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover.
etidronic acid : A 1,1-bis(phosphonic acid) that is (ethane-1,1-diyl)bis(phosphonic acid) having a hydroxy substituent at the 1-position. It inhibits the formation, growth, and dissolution of hydroxyapatite crystals by chemisorption to calcium phosphate surfaces.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The surgical approach was rejected, but the severity of symptoms and osteitis deformans biochemical activity needed a treatment; it was orientated to modify bone turnover using etidronate, a bisphosphonate, which induced clinical improvement and a decrease in serum alkaline phosphatase as well as in other bone resorption markers, without side effects." | 4.79 | [Paget's disease of bone and basilar impression associated with an Arnold-Chiari type-1 malformation]. ( de Portugal Alvarez, J; Gómez Sánchez, JC; Iglesias-Osma, C; Querol Prieto, R; Suquia Múgica, B, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arponen, H | 1 |
| Vuorimies, I | 1 |
| Haukka, J | 1 |
| Valta, H | 1 |
| Waltimo-Sirén, J | 1 |
| Mäkitie, O | 1 |
| Iglesias-Osma, C | 1 |
| Gómez Sánchez, JC | 1 |
| Suquia Múgica, B | 1 |
| Querol Prieto, R | 1 |
| de Portugal Alvarez, J | 1 |
1 review available for etidronate and Basilar Impression
| Article | Year |
|---|---|
[Paget's disease of bone and basilar impression associated with an Arnold-Chiari type-1 malformation].
Topics: Aged; Arnold-Chiari Malformation; Etidronic Acid; Female; Humans; Osteitis Deformans; Platybasia; Re | 1997 |
1 other study available for etidronate and Basilar Impression
| Article | Year |
|---|---|
Cranial base pathology in pediatric osteogenesis imperfecta patients treated with bisphosphonates.
Topics: Adolescent; Bone Density Conservation Agents; Child; Child, Preschool; Diphosphonates; Drug Administ | 2015 |